Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Researchers have identified diagnostic microRNA panels in whole blood that had the ability to distinguish, to some degree, patients with and without pancreatic cancer, according to a study in JAMA. The authors caution that the findings are preliminary, and that further research is necessary to understand whether these microRNAs have clinical implications as a screening test for early detection of pancreatic cancer.
MicroRNAs regulate gene expression and play important roles in the development of tumors and tumor metastasis. MicroRNA panels are a combination of several microRNAs.
Pancreatic cancer is the fourth most common cause of cancer death in the Western world and prognosis is poor, according to background information in the article. Early diagnosis of pancreatic cancer is difficult partly because it is difficult to get useful biopsies of tissue from patients suspected of having pancreatic cancer, so markers of the disease that could help with early diagnosis are needed to improve prognosis. Several specific microRNA profiles (patterns of microRNAs) have been linked to pancreatic cancer tissue. A diagnostic noninvasive blood test for pancreatic cancer would be very valuable, the authors write.
Nicolai A. Schultz, M.D., Ph.D., of Herlev Hospital, Copenhagen University Hospital, Copenhagen, Denmark, and colleagues examined differences in microRNA in whole blood between patients with pancreatic cancer (n = 409) and healthy participants (n = 312) and patients with chronic pancreatitis (n = 25) to identify diagnostic panels of microRNAs for use in the diagnosis of pancreatic cancer. Serum cancer antigen 19-9 (CA19-9; an antigen that is elevated in approximately 80 percent of patients with pancreatic cancer) was also measured for comparison.
The researchers identified 2 novel panels with the potential for diagnosing pancreatic cancer.
The authors write that the test could result in referral of more individuals with symptoms to imaging. "The test could thereby diagnose more patients with pancreatic cancer, some of them at an early stage, and thus have a potential to increase the number of patients that can be operated on and possibly cured of pancreatic cancer."
They add that the harms of a high number of false-positives in screening for pancreatic cancer using an inexpensive, noninvasive blood sample from individuals with or without symptoms should be quantified in the future.
"Although we validated the panels, our findings are preliminary. ... Further research is necessary to understand whether these have clinical implications for early detection of pancreatic cancer and how much this information adds to serum CA19-9."
In an accompanying editorial, Donald J. Buchsbaum, Ph.D., of the University of Alabama, Birmingham, and Carlo M. Croce, M.D., of Ohio State University, Columbus, write that additional research is needed regarding the use of microRNAs for the early detection of pancreatic cancer.
"Even though the study was relatively large, well-conducted, and addressed the important topic of development of noninvasive methods to detect pancreatic cancer, the authors appropriately acknowledge the exploratory nature of the investigation. ... Given the dismal prognosis for patients with pancreatic cancer, it is important that new diagnostic approaches, such as the one used in this study, are sought. However, additional rigorous investigation will be necessary to support and extend these interesting findings."
Article - JAMA doi:10.1001/jama.2013.284664
Editorial - JAMA doi:10.1001/jama.2013.284665
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Pancreatic Cancer category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
JAMA. "Biomarkers in blood show potential as early detection method of pancreatic cancer." Medical News Today. MediLexicon, Intl., 21 Jan. 2014. Web.
19 Apr. 2014. <http://www.medicalnewstoday.com/releases/271459>
JAMA. (2014, January 21). "Biomarkers in blood show potential as early detection method of pancreatic cancer." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/271459.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT is the registered trade mark of MediLexicon International Limited.